The following presentations were recorded during the 2016 Medical Symposium located in Paris, France at Hôpital Pitié-Salpêtrière. We are pleased to have this information to share with those that were not able to attend the meetings or that wanted to recapture some of the information shared. Thank you to the speakers that volunteered their time and information. Thanks also to the volunteers and staff that were able to create and edit the videos for all to view.
Visit the ECD Global Alliance YouTube channel for all published ECD related videos.
Presenter |
Presentation Slides |
Videos |
Corrado Campochiaro, MD |
Management of ECD Symptoms and Side Effects of Treatments |
Management of ECD Symptoms and Side Effects of Treatments |
Giulio Cavalli, MD |
Adult Onset (Infratentorial) Leukoencephalopathy as Presenting Manifestation of Erdheim-Chester Disease |
Adult Onset (Infratentorial) Leukoencephalopathy as Presenting Manifestation of Erdheim-Chester Disease |
Carine Courtillot, MD |
Endocrine manifestations in Erdheim-Chester disease |
Endocrine manifestations in Erdheim-Chester disease |
Benjamin Durham, MD |
Insights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Murine Models |
Insights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Murine Models |
Marina Ferrarini, MD |
Tailoring Treatment for Erdheim-Chester Disease: Focus on ECD |
Tailoring Treatment for Erdheim-Chester Disease: Focus on ECD |
Ronald Go, MD |
Efficacy of Cladribine (2-CdA) in the Treatment of Erdheim-Chester Disease (ECD) |
Efficacy of Cladribine (2-CdA) in the Treatment of Erdheim-Chester Disease (ECD) |
Filip Janku, MD, PhD |
Encouraging activity of MEK inhibitor trametinib in patients with Erdheim-Chester disease irrespective of BRAF mutation status
Clinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester Disease |
Encouraging activity of MEK inhibitor trametinib in patients with Erdheim-Chester disease irrespective of BRAF mutation status
Clinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester Disease |
Javier Martin, MD, PhD |
Future Genetic Studies in Erdheim-Chester disease – GWAS Study |
Future Genetic Studies in Erdheim-Chester disease – GWAS Study |
Kenneth McClain, MD, PhD |
Elevated CSF Osteopontin and Circulating Cells with BRAF Mutations in Patients with Langerhans Cell Histiocytosis-Associated Neurodegeneration -A Model for ECD? |
Elevated CSF Osteopontin and Circulating Cells with BRAF Mutations in Patients with Langerhans Cell Histiocytosis-Associated Neurodegeneration -A Model for ECD? |
Augusto Vaglio, MD, PhD |
MRI evidence of cardiac involvement in Erdheim-Chester disease |
MRI evidence of cardiac involvement in Erdheim-Chester disease |
See also the summary of presentations and information on the next ECD Medical Symposium.